Lucid Capital initiated coverage of BioXcel Therapeutics (BTAI) with a Buy rating and $66 price target BioXCel is expanding the use of its approved agitation drug, Igalmi, for at-home use and for Alzheimer’s disease, the analyst tells investors in a research note. The firm says there are 7M patients diagnosed with Alzheimer’s disease in the U.S. alone and the numbers are expected to double every 20 years with the aging population. It sees blockbuster potential for Igalmi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics target adjusted to $8 from $3 at H.C. Wainwright
- BioXcel receives positive recommendation from DSMB for SERENITY Phase 3 trial
- BioXcel Granted Nasdaq Compliance Extension Until September
- BioXcel granted extension to regain compliance with Nasdaq listing requirement
- BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments